Why is Omeros stock sliding today?
Omeros (OMER) stock fell 10.4% in after-hours trading after reporting Q3 2026 results. The company reported a GAAP net loss of $57.4 million, or $0.79 per share, due to a $62.0 million non-cash loss. Adjusted EPS of $0.06 beat estimates, and revenue exceeded expectations. A negative opinion from the European Medicines Agency on narsoplimab also weighed on sentiment.
How this was made
The 30-second read
Why it matters
The combination of GAAP loss optics and a continued European regulatory setback is presented as the primary driver of the after-hours selloff.
Market read
Company-specific earnings optics plus an EMA negative opinion are likely to dominate near-term positioning for Omeros.
What to watch
Investors may be underweighting the adjusted EPS and gross revenue beat, and overemphasizing the non-cash derivative impact relative to the underlying operating trend.
Background
Omeros reported Q3 2026 results with adjusted EPS and revenue beats, but a large GAAP net loss and a negative EMA CHMP opinion on narsoplimab for TA-TMA.
Ticker impact
Omeros shares fell 10.4% after hours after Q3 results showed a GAAP net loss of $57.4M despite adjusted EPS and revenue beats.
Likely further downside or elevated volatility as investors reprice regulatory and GAAP-loss risk versus the adjusted earnings beat.
The article ties the selloff directly to the GAAP net loss driven by non-cash derivative mark-to-market and a new European regulatory negative opinion, both immediate sentiment drivers.
Market effects
Highlights how biotech investors can punish GAAP optics and regulatory setbacks even when adjusted profitability and revenue improve.
European regulatory sentiment (EMA CHMP negative opinion) is a direct overhang for Omeros’ TA-TMA program.
Reinforces cross-market read-through that EMA decisions can quickly pressure US-listed biotech sentiment.
Counterpoint
The GAAP loss is largely non-cash from derivative mark-to-market, while operating income and adjusted EPS improved, suggesting the selloff may overreact to accounting optics.
Key entities
- companyOmeros
Seattle-based biopharmaceutical company whose Q3 results and EMA regulatory outcome drove the after-hours decline.
- regulatorEuropean Medicines Agency (EMA) CHMP
Issued a negative opinion on narsoplimab for TA-TMA after re-examination in October.
- productnarsoplimab (TA-TMA)
Therapy program referenced as receiving a negative EMA opinion, weighing on sentiment.


